Lv7
3790 积分 2024-02-08 加入
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
1个月前
已完结
Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
1个月前
已完结
A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma
1个月前
已关闭
Survival of patients with marginal zone lymphoma
3个月前
已关闭
The Treatment of Marginal Zone Lymphoma
3个月前
已完结
Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
4个月前
已完结
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges
6个月前
已完结
Advances in Primary Central Nervous System Lymphoma
6个月前
已完结
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
8个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
10个月前
已完结
皖公网安备34019202002308
